ChromoTrax is an international biomedical research and development company dedicated to developing innovative technologies and products to improve diagnosis and treatment of patients suffering from genetic-based diseases including cancers. The company’s name, ChromoTrax, reflects the functions of its core technologies – detecting chromosome aberrations through use of colors. The Company possesses two proprietary technologies: Repeat Sequence Deplete DNA probes (ReSeD), and Hybridization in Suspension (informally called Cyto-Flo). Both technologies are fully developed: ReSeD is ready for commercial sales, and Cyto-Flo is in clinical validation stage.
ChromoTrax has successfully completed Phase I and Phase II Small Business Innovation Research grants (SBIRs) from the Department of Defense, a Phase I SBIR from National Cancer Institute (NCI) for the development of its proprietary Hybridization in Suspension technology and its applications to cancer detection.